Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 3/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30887615 | 1.00 | KDM4E (0.38) | KDM4EPOLBLMNAGAANPC1 | |
| SCHEMBL20527164 | 1.00 | KDM4E (0.38) | KDM4EPOLBLMNAGAANPC1 | |
| SCHEMBL21840253 | 0.98 | KDM4E (0.39) | KDM4EPOLBLMNAGAANPC1 | |
| SCHEMBL29687429 | 0.98 | KDM4E (0.39) | KDM4EPOLBLMNAGAANPC1 | |
| SCHEMBL21840252 | 0.98 | KDM4E (0.39) | KDM4EPOLBLMNAGAANPC1 | |
| SCHEMBL22443262 | 0.94 | KDM4E (0.40) | KDM4EPOLBLMNAGAANPC1 | |
| SCHEMBL22443263 | 0.94 | KDM4E (0.40) | KDM4EPOLBLMNAGAANPC1 | |
| SCHEMBL4412576 | 0.90 | KDM4E (0.44) | KDM4EPOLBLMNAGAAHCRTR1 | |
| SCHEMBL14071791 | 0.90 | KDM4E (0.44) | KDM4EPOLBLMNAGAAHCRTR1 | |
| SCHEMBL29424505 | 0.89 | KDM4E (0.37) | KDM4EPOLBLMNAGAANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11912700-B2 | Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | PHEON THERAPEUTICS LTD (GB) | 2024-02-27 | — | — | US | disclosed |
| US-20210206763-A1 | Anti-Proliferative Agents | PHEON THERAPEUTICS LTD (GB) | 2021-07-08 | — | — | US | disclosed |
| US-10975072-B2 | Substituted 6a,7,8,9,10,12-hexahydrobenzo[e]pyrido[1,2-a][1,4]diazepines as anti-proliferative agents | FEMTOGENIX LIMITED | 2021-04-13 | — | — | US | disclosed |
| US-10975074-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | FEMTOGENIX LIMITED | 2021-04-13 | — | — | US | disclosed |
| US-20190308970-A1 | ANTI-LIFERATIVE AGENTS COMPRISING SUBSTITUTED PYRROLO-, INDOLINO- OR TETRAHYDROISOQUINOLINE-BENZODIAZEPINES | PHEON THERAPEUTICS LTD (GB) | 2019-10-10 | — | — | US | disclosed |
| US-20180339985-A1 | PDD COMPOUNDS | FEMTOGENIX LIMITED (GB) | 2018-11-29 | — | — | US | disclosed |
| US-20180291021-A1 | PDD COMPOUNDS | PHEON THERAPEUTICS LTD (GB) | 2018-10-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206763-A1 | Anti-Proliferative Agents | CCND2, BRD2, DRD2 | KDM4E 1175/4885POLB 127/4885LMNA 2614/4885 |
| US-10975074-B2 | Anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | CNR1, GABRA1, BAK1 | KDM4E 868/4885POLB 307/4885LMNA 871/4885 |
| US-10975072-B2 | Substituted 6a,7,8,9,10,12-hexahydrobenzo[e]pyrido[1,2-a][1,4]diazepines as anti-proliferative agents | PDCD1, CCND1, PDCD6 | KDM4E 1020/4885POLB 876/4885LMNA 3701/4885 |
| US-20190308970-A1 | ANTI-LIFERATIVE AGENTS COMPRISING SUBSTITUTED PYRROLO-, INDOLINO- OR TETRAHYDROISOQUINOLINE-BENZODIAZEPINES | GABRA1, GABBR1, GABRA2 | KDM4E 1164/4885POLB 382/4885LMNA 1734/4885 |
| US-20180291021-A1 | PDD COMPOUNDS | DRD1, DRD3, DRD2 | KDM4E 2551/4885POLB 1536/4885LMNA 2940/4885 |
| US-11912700-B2 | Anti-proliferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines | MKI67, CCND2, CCND1 | KDM4E 684/4885POLB 231/4885LMNA 1477/4885 |
| US-20180339985-A1 | PDD COMPOUNDS | DRD1, DRD3, DRD2 | KDM4E 2367/4885POLB 1301/4885LMNA 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.